Drug · CHEMBL239243
TAURINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. TAURINE. Drugs and targets, record CHEMBL239243. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL239243
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Aminoethylsulfonic acid, Ethanesulfonic acid, 2-amino-, FEMA NO. 3813, NSC-32428, Taurate, Taurina
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases16
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 16Source Open Targets
See all 16 diseasesTrials22
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01192828 | Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine | Phase 1/2 | 15 | 2018-07-09 | taurine | Its name | ClinicalTrials.gov |
| NCT06721949 | Taurine Supplementation in Long COVID | Phase 2/3 | 300 | taurine | Its name | ClinicalTrials.gov | |
| NCT03410173 | Taurine Supplementation on Cognitive Function in Patients With Diabetes | 200 | taurine | Its name | ClinicalTrials.gov | ||
| NCT03410537 | Taurine Supplementation on Lower Extremity Vasculopathy in Patients With Diabetes | 200 | taurine | Its name | ClinicalTrials.gov | ||
| NCT02418130 | A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of 'Ursa Complex Soft Cap. (UDCA-004)' in Patients With Physical Fatigue. | Phase 4 | 166 | taurine | Its name | ClinicalTrials.gov | |
| NCT07029178 | Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis | Phase 2 | 160 | taurine | Its name | ClinicalTrials.gov | |
| NCT07567742 | Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma | Phase 2 | 130 | taurine | Its name | ClinicalTrials.gov | |
| NCT00420823 | A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment | Phase 2/3 | 121 | taurine | Its name | ClinicalTrials.gov | |
| NCT01816698 | Effects and Safety of Taurine Granule on Blood Pressure in Prehypertensive | Phase 3 | 120 | taurine | Its name | ClinicalTrials.gov | |
| NCT06128252 | Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer | 96 | taurine | Its name | ClinicalTrials.gov |
1 to 10 of 22
See all 22 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials1
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 27835719 | DERIVED | 1 |
Source PubMed
Tests in its trials2
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Trail Making Test A | 1 | 1 | ConductCognition |
| Trail Making Test B | 1 | 1 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL239243
GET https://conductscience.org/api/drugs/v1/CHEMBL239243/trials?page=2